Modular Automation Moves from Vision to GMP Reality
A pharma project demonstrates how MTP can accelerate integration while reducing validation effort.
pharma manufacturing
How FDA's PreCheck Pilot Aims to Speed Up US Drug Manufacturing
DCAT reports that FDA has selected seven companies for its new PreCheck Pilot Program, designed to encourage US-based drug manufacturing through earlier engagement and a more predictable regulatory path.
Fujifilm Biotechnologies Selected for FDA PreCheck Pilot Program to Advance US Drug Manufacturing
Fujifilm Biotechnologies' Holly Springs, NC facility has been chosen as one of seven participants in the FDA's PreCheck Pilot Program, aimed at strengthening US pharmaceutical manufacturing and regulatory readiness.
Innexis Acquires Novartis's Kundl Site
Innexis plans to acquire the multi-user facility in Kundl, Tyrol, from Novartis.
Pharma 4.0: Big Promises, Poor Data - What’s Going Wrong?
Pharma 4.0 is high on every strategic agenda. Yet many struggle to turn digital ambitions into measurable results. Projects stall, systems don’t align, and valuable insights remain locked in fragmented data structures.
AbbVie to Acquire Arizona Manufacturing Facility
AbbVie will acquire West Pharmaceutical Services’ Tempe, Arizona, manufacturing facility for over $175 million to expand US drug delivery device capacity, with closing expected mid-2026.
ACG Invests $200 Million in US Hard-Shell Capsule Manufacturing
The investment will focus on developing gelatin and HPMC facilities, creating over 200 new jobs, and strengthening ACG’s 25-year presence in the US, with operations expected to begin in early 2027.
GSK to Invest $30 Billion in US R&D and Manufacturing
Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.
Gilead Breaks Ground on New US Manufacturing Hub
New Bay Area building marks significant progress as part of Gilead's $32 billion US investment.
AstraZeneca to Invest $50 Billion in US Manufacturing
AstraZeneca recently announced $50 billion of investment in the US by 2030. This investment is expected to create tens of thousands of new, highly skilled jobs nationwide.
Quality and Safety in Biopharmaceutical Production
The biopharmaceutical industry is experiencing a drive towards biologic products due to their promise as treatments for chronic diseases.
The Impact of Covid-19 on the Pharmaceutical Industry
Andrew Badrot, CEO of C2 Pharma and a close observer of pharma industry trends, analyzes the current situation and how this pandemic may kick of changes in the pharma market.
